Anna Wolska

Anna Wolska, MS, PhD, FAHA, serves as a Staff Scientist at the National Heart, Lung, and Blood Institute since September 2014, focusing on new treatments for hyperlipidemia and co-inventing relevant U.S. patents. Wolska has held various research and leadership roles, including Research Fellow and Technology Transfer Fellow, and has contributed significantly to the field through peer-review activities for prestigious journals like the European Heart Journal and the Journal of the American College of Cardiology. In addition to ongoing roles such as a Visiting Researcher with the Lupus Foundation of America and Editorial Board Member for the Lipids in Health and Disease journal, Wolska also serves as the Communications Officer for the Lipoproteins and Vascular Diseases Division of the American Association for Clinical Chemistry. Educational credentials include a PhD in Medical Biology and certifications in clinical chemistry and laboratory diagnostics from the Medical University of Gdańsk.